Acquiring Company
Multiplex Bio
Acquired Company
Standard BioTools
BostonSan FranciscoManufacturingBiotechnologyBiotechnologyHealth CareDescription
Standard BioTools has announced the sale of its Mass Cytometry business to Multiplex Bio. The deal ensures continuity of the product lines and a dedicated team. Additionally, Standard BioTools receives $30 million related to Illumina's acquisition of its SomaLogic business. This acquisition promotes ongoing investment in next-generation multiplex platforms.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Standard BioTools?
Standard BioTools was acquired by Multiplex Bio, based in Boston. The deal was reported on July 28, 2026. Multiplex Bio focuses on the commercialization of advanced imaging products. Founded by industry veterans, it aims to maintain continuity of customer relationships and product lines. Multiplex Bio is privately held and operates in Manufacturing.
When did Multiplex Bio acquire Standard BioTools?
Multiplex Bio's acquisition of Standard BioTools was reported on July 28, 2026. Standard BioTools has announced the sale of its Mass Cytometry business to Multiplex Bio. The deal ensures continuity of the product lines and a dedicated team. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Standard BioTools do?
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc., has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. It is publicly traded (LAB), operating in Biotechnology, and is based in San Francisco.